For adults with refractory or unexplained chronic cough, gefapixant leads to modest improvement in cough frequency, severity, and quality of life, according to a review published online Sept. 11 in the Journal of the American ...
Sep 11, 2023
0
1
The combination of benmelstobart, anlotinib, and chemotherapy demonstrated significant benefits compared to placebo and chemotherapy in terms of median progression-free survival and overall survival for patients with extensive-stage ...
Sep 11, 2023
0
1
Many people with diseases such as cancer or diabetes or those who have had a heart attack or stroke also suffer from depression. How effective are antidepressants for these patients? And are they just as safe for these people ...
Sep 7, 2023
0
8
A prominent childhood memory is of my grandparents living with and then dying from dementia. As is universal with dementia, there was a double blow: watching my grandparents lose their identity and seeing the suffering of ...
Sep 1, 2023
0
2
A trial led by the Duke Clinical Research Institute, Durham, has investigated the long-term safety and efficacy of supplementing heart failure patients with iron.
Hot flashes are one of the most concerning and most reported symptoms among menopausal women and breast cancer survivors. Currently, paroxetine is a FDA-approved non-hormonal drug used for the treatment of hot flashes. In ...
Aug 29, 2023
0
14
Anticoagulation after primary percutaneous coronary intervention (PCI) does not prevent adverse outcomes in patients with ST-segment elevation myocardial infarction (STEMI), according to late breaking research presented in ...
Aug 29, 2023
0
1
Acoramidis improves outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
Aug 28, 2023
1
2
Extended P2Y12 inhibitor monotherapy beyond 12 months after percutaneous coronary intervention (PCI) reduces bleeding and ischemic events in acute coronary syndrome (ACS) patients at high risk for both types of events. That's ...
Aug 28, 2023
0
28
Ferric carboxymaltose (FCM) did not improve a hierarchical outcome of death, heart failure hospitalizations and exercise function in ambulatory patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, ...
Aug 28, 2023
0
23
